Trials / Completed
CompletedNCT00557323
Long-term Effect of Lanthanum Carbonate on Bone
A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 34 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum carbonate |
Timeline
- Start date
- 2007-03-15
- Primary completion
- 2010-08-31
- Completion
- 2010-08-31
- First posted
- 2007-11-14
- Last updated
- 2021-07-13
- Results posted
- 2011-06-15
Locations
19 sites across 3 countries: United States, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00557323. Inclusion in this directory is not an endorsement.